Amazon adds generic prescription perk for Prime members

Amazon adds generic prescription perk for Prime members


Amazon launches RxPass; new prescription perk for U.S. Prime members

Amazon on Tuesday announced a new prescription perk for U.S. Prime members, hoping to boost subscriptions and attract users to its pharmacy service.

The add-on, called RxPass, will allow Prime members to get as many drugs as they need from a list of 50 generic medications to treat more than 80 common chronic conditions, such as high blood pressure, anxiety and diabetes. The service costs $5 a month per person, and delivery is free.

Amazon has pushed deeper into health care in recent years. The company launched its own online pharmacy in 2020, a service that was born out of its acquisition of PillPack in 2018. Amazon introduced, then shuttered, a telehealth service called Amazon Care, and announced in July it would acquire boutique primary care provider One Medical.

Amazon also offers a Prime prescription savings benefit, which offers a discount of up to 80% on generic medications and up to 40% on brand-name prescriptions.

Amazon is beefing up perks for its Prime subscription program as CEO Andy Jassy looks to cut costs elsewhere in the company. Amazon has eyed laying off about 18,000 employees, while it froze hiring in its corporate workforce and axed some projects. Still, Jassy has said Amazon intends to keep pursuing long-term opportunities, including health care.

The e-retailer faces competition in pharmacy from the likes of CVS, Walgreens and Walmart. Amazon hasn’t said how its online pharmacy offering has fared since its launch. An August report from Morgan Stanley found Amazon Pharmacy didn’t rank as a top perk for Prime members, based on a survey of users, according to Business Insider.

Amazon Pharmacy’s chief medical officer, Vin Gupta, said the company is aiming to deliver a pharmacy experience that is “fundamentally different” from how pharmacies have existed over the last several decades.

“This is still day one for us where we’re at our beginning stages here, but we recognize that change is needed,” Gupta said in an interview. “That’s what patients across the country are telling us, and that’s what Amazon is responding to.”

RxPass doesn’t offer insulin or specialty medications, and it’s not available for people on Medicaid or Medicare. Gupta declined to say whether Amazon will expand the list of medications offered through RxPass in the future.

Approximately 150 million people are on at least one of the medications included in the initial RxPass formulary, he said.

— CNBC’s Bertha Coombs contributed to this article.



Source

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
Health

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Analysts say […]

Read More
Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits
Health

Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits

Robert F. Kennedy Jr. attends a campaign event for Republican presidential nominee and former U.S. President Donald Trump in Milwaukee, Wisconsin, U.S. November 1, 2024.  Joel Angel Juarez | Reuters Dental care supplier Henry Schein advanced in Monday trading as investors bet that Robert F. Kennedy Jr., President-elect Donald Trump’s pick for Health and Human […]

Read More
2 health stocks are buys. They’ve been beaten up enough on Trump’s RFK Jr. pick for HHS
Health

2 health stocks are buys. They’ve been beaten up enough on Trump’s RFK Jr. pick for HHS

We are buying 25 shares of Danaher at roughly $229 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 550 shares of DHR, increasing its weighting to roughly 3.6% from 3.4%. The health care sector has been the big loser in the market since the election. If the SPDR Health Care Sector Fund , […]

Read More